Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Arginine HELP
Based on 13,280 articles published since 2008
||||

These are the 13280 published articles about Arginine that originated from Worldwide during 2008-2018.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. 2016

Levy, J H / Ageno, W / Chan, N C / Crowther, M / Verhamme, P / Weitz, J I / Anonymous5050859. ·Duke University School of Medicine, Durham, NC, USA. · University of Insubria, Varese, Italy. · Monash University, Clayton, Vic., Australia. · McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada. · University of Leuven, Leuven, Belgium. ·J Thromb Haemost · Pubmed #26911798.

ABSTRACT: -- No abstract --

2 Guideline A.S.P.E.N. clinical guidelines: nutrition support of neonatal patients at risk for necrotizing enterocolitis. 2012

Fallon, Erica M / Nehra, Deepika / Potemkin, Alexis K / Gura, Kathleen M / Simpser, Edwin / Compher, Charlene / Anonymous9870730 / Puder, Mark. ·Department of Surgery and The Vascular Biology Program, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA. ·JPEN J Parenter Enteral Nutr · Pubmed #22753618.

ABSTRACT: BACKGROUND: Necrotizing enterocolitis (NEC) is one of the most devastating diseases in the neonatal population, with extremely low birth weight and extremely preterm infants at greatest risk. METHOD: A systematic review of the best available evidence to answer a series of questions regarding nutrition support of neonates at risk of NEC was undertaken and evaluated using concepts adopted from the Grading of Recommendations, Assessment, Development and Evaluation working group. A consensus process was used to develop the clinical guideline recommendations prior to external and internal review and approval by the A.S.P.E.N. Board of Directors. RESULTS/ CONCLUSIONS: (1) When and how should feeds be started in infants at high risk for NEC? We suggest that minimal enteral nutrition be initiated within the first 2 days of life and advanced by 30 mL/kg/d in infants ≥ 1, 000 g. (Weak) (2) Does the provision of mother's milk reduce the risk of developing NEC? We suggest the exclusive use of mother's milk rather than bovine-based products or formula in infants at risk for NEC. (Weak) (3) Do probiotics reduce the risk of developing NEC? There are insufficient data to recommend the use of probiotics in infants at risk for NEC. (Further research needed.) (4) Do nutrients either prevent or predispose to the development of NEC? We do not recommend glutamine supplementation for infants at risk for NEC (Strong). There is insufficient evidence to recommend arginine and/or long chain polyunsaturated fatty acid supplementation for infants at risk for NEC. (Further research needed.) (5) When should feeds be reintroduced to infants with NEC? There are insufficient data to make a recommendation regarding time to reintroduce feedings to infants after NEC. (Further research needed.).

3 Guideline [Guidelines for specialized nutritional and metabolic support in the critically-ill patient. Update. Consensus of the Spanish Society of Intensive Care Medicine and Coronary Units-Spanish Society of Parenteral and Enteral Nutrition (SEMICYUC-SENPE): patient with sepsis]. 2011

Ortiz Leyba, C / Montejo González, J C / Vaquerizo Alonso, C / Anonymous3670717. ·Hospital Universitario Virgen del Rocío, Sevilla, España. carlos.ortiz.sspa@juntadeandalucia.es ·Med Intensiva · Pubmed #22309758.

ABSTRACT: Nutritional metabolic management, together with other treatment and support measures used, is one of the mainstays of the treatment of septic patients. Nutritional support should be started early, after initial life support measures, to avoid the consequences of malnutrition, to provide adequate nutritional intake and to prevent the development of secondary complications such as superinfection or multiorgan failure. As in other critically-ill patients, when the enteral route cannot be used to ensure calorie-protein requirements, the association of parenteral nutrition has been shown to be safe in this subgroup of patients. Studies evaluating the effect of specific pharmaconutrients in septic patients are scarce and are insufficient to allow recommendations to be made. To date, enteral diets with a mixture of substrates with distinct pharmaconutrient properties do not seem to be superior to standard diets in altering the course of sepsis, although equally there is no evidence that these diets are harmful. There is insufficient evidence to recommend the use of glutamine in septic patients receiving parenteral nutrition. However, given the good results and absence of glutamine-related adverse effects in the various studies performed in the general population of critically-ill patients, these patients could benefit from the use of this substance. Routine use of omega-3 fatty acids cannot be recommended until further evidence has been gathered, although the use of lipid emulsions with a high omega-6 fatty acid content should be avoided. Septic patients should receive an adequate supply of essential trace elements and vitamins. Further studies are required before the use of high-dose selenium can be recommended.

4 Guideline [Guidelines for specialized nutritional and metabolic support in the critically-ill patient. Update. Consensus of the Spanish Society of Intensive Care Medicine and Coronary Units-Spanish Society of Parenteral and Enteral Nutrition (SEMICYUC-SENPE): gastrointestinal surgery]. 2011

Sánchez Álvarez, C / Zabarte Martínez de Aguirre, M / Bordejé Laguna, L / Anonymous3600717. ·Hospital General Universitario Reina Sofía, Murcia, España. carmen.sanchez6@telefonica.net ·Med Intensiva · Pubmed #22309752.

ABSTRACT: Gastrointestinal surgery and critical illness place tremendous stress on the body, resulting in a series of metabolic changes that may lead to severe malnutrition, which in turn can increase postsurgical complications and morbidity and mortality and prolong the hospital length of stay. In these patients, parenteral nutrition is the most widely used form of nutritional support, but administration of enteral nutrition early in the postoperative period is effective and well tolerated, reducing infectious complications, improving wound healing and reducing length of hospital stay. Calorie-protein requirements do not differ from those in other critically-ill patients and depend on the patient's underlying process and degree of metabolic stress. In patients intolerant to enteral nutrition, especially if the intolerance is due to increased gastric residual volume, prokinetic agents can be used to optimize calorie intake. When proximal sutures are used, tubes allowing early jejunal feeding should be used. Pharmaconutrition is indicated in these patients, who benefit from enteral administration of arginine, omega 3 and RNA, as well as parenteral glutamine supplementation. Parenteral nutrition should be started in patients with absolute contraindication for use of the gastrointestinal tract or as complementary nutrition if adequate energy intake is not achieved through the enteral route.

5 Guideline The CARI guidelines. Nutritional management of hypertension in adult kidney transplant recipients. 2010

Chadban, Steven / Chan, Maria / Fry, Karen / Patwardhan, Aditi / Ryan, Catherine / Trevillian, Paul / Westgarth, Fidye / Anonymous4720664. · ·Nephrology (Carlton) · Pubmed #20591046.

ABSTRACT: -- No abstract --

6 Editorial Immunonutrition and Colorectal Surgery. 2017

McClave, Stephen A / Martindale, Robert G / Maxwell, John P. ·Louisville, Kentucky Portland, Oregon Charleston, South Carolina. ·Dis Colon Rectum · Pubmed #27926550.

ABSTRACT: -- No abstract --

7 Editorial Asymmetric dimethylarginine: a risk indicator or pathogenic factor? 2016

Fuchs, Dietmar / Kurz, Katharina / Gostner, Johanna M. · ·Pol Arch Med Wewn · Pubmed #27698330.

ABSTRACT: -- No abstract --

8 Editorial Ciraparantag for enoxaparin reversal: Adding to the evidence. 2016

Weitz, Jeffrey I / Eikelboom, John W. ·McMaster University, Canada; Thrombosis and Atherosclerosis Research Institute, Canada. Electronic address: weitzj@taari.ca. · McMaster University, Canada; Thrombosis and Atherosclerosis Research Institute, Canada; Population Health Research Institute, Canada. ·Thromb Res · Pubmed #27544033.

ABSTRACT: -- No abstract --

9 Editorial Renal blood flow autoregulation: what are the contributions for nitric oxide or superoxide to modulate the myogenic response? 2016

Imig, John D. ·Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin jdimig@mcw.edu. ·Am J Physiol Renal Physiol · Pubmed #26962100.

ABSTRACT: -- No abstract --

10 Editorial The neuroprotective potential of arginine-rich peptides for the acute treatment of traumatic brain injury. 2016

Chiu, Li Shan / Anderton, Ryan S / Knuckey, Neville W / Meloni, Bruno P. ·a Western Australian Neuroscience Research Institute , Nedlands , Australia. · b Centre for Neuromuscular and Neurological Disorders , The University of Western Australia , Nedlands , Australia. · c School of Heath Sciences , The University Notre Dame Australia , Fremantle , Western Australia , Australia. · d Department of Neurosurgery , Sir Charles Gairdner Hospital, QEII Medical Centre , Nedlands , Western Australia , Australia. ·Expert Rev Neurother · Pubmed #26840929.

ABSTRACT: -- No abstract --

11 Editorial The Quest for Metabolic Biomarkers of Pulmonary Hypertension. 2016

Calvo, Enrique / García-Álvarez, Ana / Vázquez, Jesús. ·Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain. · Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain. Electronic address: jvazquez@cnic.es. ·J Am Coll Cardiol · Pubmed #26791066.

ABSTRACT: -- No abstract --

12 Editorial [Antidotes for the new oral anticoagulants: Reality and expectations]. 2016

Gómez-Outes, Antonio / Lecumberri, Ramón. ·División de Farmacología y Evaluación Clínica, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, España. Electronic address: agomezo@aemps.es. · Servicio de Hematología, Clínica Universidad de Navarra, Pamplona, Navarra, España. ·Med Clin (Barc) · Pubmed #26776485.

ABSTRACT: -- No abstract --

13 Editorial Homoarginine, arginine, and relatives: analysis, metabolism, transport, physiology, and pathology. 2015

Tsikas, Dimitrios / Wu, Guoyao. ·Centre of Pharmacology and Toxicology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany, tsikas.dimitros@mh-hannover.de. ·Amino Acids · Pubmed #26210755.

ABSTRACT: The year 2008 witnessed the first report on the increase in the concentration of L-homoarginine (hArg) in the maternal plasma during human pregnancy. This observation, along with a well-known function of hArg, the methylene homologue of L-arginine (Arg), as a substrate for nitric oxide (NO) synthase, was the ignition for the start of intense research on the physiology and pathology of hArg. The circulating concentration of hArg was found to be lower in patients suffering from various diseases, and hArg emerged within only very few years as a novel cardiovascular risk factor. The compendium in hand comprises original and review articles covering several aspects of hArg, Arg and its symmetrically and asymmetrically guanidine (N (G))-dimethylated derivatives SDMA and ADMA, respectively. In contrast to ADMA and SDMA, low hArg concentrations in plasma or serum and in urine are associated with high risks for morbidity and mortality, notably in the renal and cardiovascular systems. Acutely and chronically administered Arg as a nutritional supplement or in the form of dietary proteins is safe in animals and humans and leads to concomitant formation of hArg and ADMA, albeit in a different hArg/ADMA ratio. Despite the close but opposite associations of hArg and ADMA with disease in adults, children and adolescents, the underlying biochemical processes are largely unknown, presumably not restricted to NO, and warrant deeper investigation. As the common substrate for hArg and ADMA, Arg may play a key role in the biosynthesis and homeostasis of hArg and ADMA, two putative antagonists. In animal models of stroke and obesity, hArg has beneficial effects. The potential utility of hArg as a therapeutic drug or nutritional supplement in humans and animals remains to be elaborated.

14 Editorial May the Force Be with You: Metabolism of Arginine and Pyrimidines. 2015

Liu, Ji-Long. ·Medical Research Council Functional Genomics Unit, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, United Kingdom. Electronic address: jilong.liu@dpag.ox.ac.uk. ·J Genet Genomics · Pubmed #26059766.

ABSTRACT: -- No abstract --

15 Editorial Liver plays a central role in asymmetric dimethylarginine-mediated organ injury. 2015

Ferrigno, Andrea / Di Pasqua, Laura G / Berardo, Clarissa / Richelmi, Plinio / Vairetti, Mariapia. ·Andrea Ferrigno, Laura G Di Pasqua, Clarissa Berardo, Plinio Richelmi, Mariapia Vairetti, Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy. ·World J Gastroenterol · Pubmed #25954086.

ABSTRACT: Asymmetric-dimethylarginine (ADMA) competes with L-arginine for each of the three isoforms of nitric oxide synthase: endothelial; neuronal; inducible. ADMA is synthesized by protein methyltransferases followed by proteolytic degradation. ADMA is metabolized to citrulline and dimethylamine, by dimethylarginine dimethylaminohydrolase (DDAH) and enters cells through cationic amino-acid transporters extensively expressed in the liver. The liver plays a crucial role in ADMA metabolism by DDAH-1 and, as has been recently demonstrated, it is also responsible for ADMA biliary excretion. A correlation has been demonstrated between plasma ADMA levels and the degree of hepatic dysfunction in patients suffering from liver diseases with varying aetiologies: plasma ADMA levels are increased in patients with liver cirrhosis, alcoholic hepatitis and acute liver failure. The mechanism by which liver dysfunction results in raised ADMA concentrations is probably due to impaired activity of DDAH due to severe inflammation, oxidative stress, and direct damage to DDAH. High plasma ADMA levels are also relevant as they are associated with the onset of multi-organ failure (MOF). Increased plasma concentration of ADMA was identified as an independent risk factor for MOF in critically-ill patients causing enhanced Intensive Care Unit mortality: a significant reduction in nitric oxide synthesis, leading to malperfusion in various organs, eventually culminating in multi organs dysfunction.

16 Editorial Asymmetric dimethylarginine reflects cumulative inflammatory burden in rheumatoid arthritis. A novel mechanism of excessive cardiovascular morbidity? 2015

Włoch, Alicja / Wieczorek-Surdacka, Ewa / Sulicka-Grodzicka, Joanna / Kruszelnicka, Olga / Surdacki, Andrzej. ·Małopolska Center for Rheumatology, Immunology and Rehabilitation, J. Dietl Hospital in Kraków, Department of Nephrology, Department of Rheumatology and Balneology, Jagiellonian University Medical College and University Hospital, Department of Coronary Artery Disease and Heart Failure, John Paul II Hospital in Kraków and Second Department of Cardiology, Jagiellonian University Medical College and University Hospital, Kraków, Poland. · Małopolska Center for Rheumatology, Immunology and Rehabilitation, J. Dietl Hospital in Kraków, Department of Nephrology, Department of Rheumatology and Balneology, Jagiellonian University Medical College and University Hospital, Department of Coronary Artery Disease and Heart Failure, John Paul II Hospital in Kraków and Second Department of Cardiology, Jagiellonian University Medical College and University Hospital, Kraków, Poland surdacki.andreas@gmx.net. ·Rheumatology (Oxford) · Pubmed #25922548.

ABSTRACT: -- No abstract --

17 Editorial Exercise-induced cardioprotection: more to k‘NO’w. 2015

Lira, Vitor A. · ·Cardiology · Pubmed #25720747.

ABSTRACT: -- No abstract --

18 Editorial Plasma asymmetric dimethylarginine in infants with bronchopulmonary dysplasia: a promising biomarker despite uncertain pathogenic significance. 2015

Aschner, Judy L / Fike, Candice D. ·Department of Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, New York. Electronic address: judy.aschner@einstein.yu.edu. · Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee. ·J Pediatr · Pubmed #25454308.

ABSTRACT: -- No abstract --

19 Editorial Does Smad6 methylation control BMP signaling in cancer? 2014

Xu, Jian / Derynck, Rik. ·Department of Cell and Tissue Biology and Department of Anatomy; Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research; University of California, San Francisco; San Francisco, CA USA. ·Cell Cycle · Pubmed #24621505.

ABSTRACT: -- No abstract --

20 Editorial I. Peripheral endothelial dysfunction after subarachnoid haemorrhage: what the fingertips can tell us. 2014

Scherbakov, N / Doehner, W. ·Center for Stroke Research Berlin, Charité-Universitätsmedizin, Berlin, Germany. ·Br J Anaesth · Pubmed #24431348.

ABSTRACT: -- No abstract --

21 Editorial Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease. 2013

Franceschelli, Sara / Ferrone, Alessio / Pesce, Mirko / Riccioni, Graziano / Speranza, Lorenza. ·Department of Medicine and Science of Aging, University G. D'Annunzio-Chieti, Chieti 66100, Italy. l.speranza@unich.it. ·Int J Mol Sci · Pubmed #24351825.

ABSTRACT: There is growing evidence that increased levels of the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) may contribute to endothelial dysfunction. Studies in animal models as well as in humans have suggested that the increase in ADMA occurs at a time when vascular disease has not yet become clinically evident. ADMA competitively inhibits NO elaboration by displacing L-arginine from NO synthase. In a concentration-dependent manner, it thereby interferes not only with endothelium-dependent, NO-mediated vasodilation, but also with other biological functions exerted by NO. The upshot may be a pro-atherogenic state. Recently, several studies have investigated the effect of various therapeutical interventions on ADMA plasma concentrations.

22 Editorial [Application of immune nutrition in patients with gastrointestinal tumors]. 2013

Wu, Guo-hao. ·Department of General Surgery, Zhongshan Hospital, Research Institute of General Surgery, Fudan University, Shanghai 200032, China. prowugh@163.com. ·Zhonghua Wei Chang Wai Ke Za Zhi · Pubmed #24277392.

ABSTRACT: Immune nutrition refers to adding some special nutrients to the standard formula of nutrition in order to treat and regulate metabolism and immune function by its pharmacological effect. In recent years, immune nutrition, including glutamine, arginine, ω-3 PUFA, nucleotide etc, has been widely used in patients with gastrointestinal cancer. These nutrients show their different supporting functions through different mechanisms, and improve the clinical outcome of patients. Therefore, clinical nutrition has been expanded and upgraded from the traditional "nutrition" to "nutritional therapy".

23 Editorial Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension? 2013

Simon, Daniel I / Simon, Norman M. ·Department of Medicine, Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH (D.I.S.) · and Division of Nephrology and Hypertension, North Shore University Health System, Evanston, IL (N.M.S.). ·Circulation · Pubmed #24092816.

ABSTRACT: -- No abstract --

24 Editorial R is for arginine: metabolism of arginine takes off again, in new directions. 2013

Michel, Thomas. ·Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. ·Circulation · Pubmed #24004503.

ABSTRACT: -- No abstract --

25 Editorial Asymmetric dimethylarginine: a disease marker for asthma? 2013

Scott, Jeremy A / Grasemann, Hartmut. ·Department of Health Sciences, Faculty of Health and Behavioural Sciences, Lakehead University, Thunder Bay, ON, Canada; Division of Medical Sciences, Northern Ontario School of Medicine, Thunder Bay, ON, Canada. · Division of Respiratory Medicine, Department of Pediatrics, and Program in Physiology and Experimental Medicine, SickKids Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. Electronic address: hartmut.grasemann@sickkids.ca. ·Chest · Pubmed #23918098.

ABSTRACT: -- No abstract --

Next